AstraZeneca plc Price Target Increased to GBX 4,000 by Analysts at Barclays (AZN)
Barclays hoisted their target price on shares of AstraZeneca plc (LON:AZN) from GBX 3,800 ($63.92) to GBX 4,000 ($67.28) in a research note issued on Wednesday. The firm currently has an “equal weight” rating on the stock. Barclays’ price objective points to a potential downside of 7.16% from the stock’s previous close.
AstraZeneca plc (LON:AZN) opened at 4389.00 on Wednesday. AstraZeneca plc has a one year low of GBX 3028.50 and a one year high of GBX 5750.00. The stock’s 50-day moving average is GBX 4232.04 and its 200-day moving average is GBX 3849.43. The company’s market cap is £55.345 billion.
AZN has been the subject of a number of other recent research reports. Analysts at BNP Paribas reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Tuesday. They now have a GBX 3,500 ($58.87) price target on the stock. Separately, analysts at Beaufort Securities reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Tuesday. Finally, analysts at Liberum Capital reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Tuesday. They now have a GBX 5,800 ($97.56) price target on the stock. Six research analysts have rated the stock with a sell rating, eighteen have issued a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of GBX 4,095.91 ($68.90).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.